Back

prof. dr. K.P.M. (Karijn) Suijkerbuijk

prof. dr. K.P.M. (Karijn) Suijkerbuijk

Full Professor
prof. dr. K.P.M. (Karijn) Suijkerbuijk
  • Department of Medical Oncology

Biography

Biography

Karijn Suijkerbuijk is a translational medical oncologist with special interest in melanoma and immunotherapy. During her PhD, she performed research on tumor epigenetics in breast cancer in the lab of Professor Saraswati Sukumar at the Sidney Kimmel Cancer Center at Johns Hopkins University. Dr. Suijkerbuijk currently participates in multiple phase II and III clinical trials on immune checkpoint inhibitors. She published papers in Oncogene, Annals of Oncology and JNCI, received research grants from KWF and NWO and was awarded an ASCO Merit Award. Her current research focuses on clinical and immunological parameters assoaciated with immune related adverse events during checkpoint inhibition and clinicopathological factors associated with checkpoint inhibitor response.

Side Activities

2023-... Scientific Steering Committee ESMO 2024 (melanoma track chair)

2023-... Chair ESMO Melanoma Faculty

2022-... Member ESMO Real World Data Working Group

2022   Research funding Bristol Myers Squibb

2021-.. Scientific advisory board Maarten vd Weijden foundation

2021-..  ESMO melanoma faculty

2021     Organizer and chair Oncode Melanoma Workshop

2021     Reserach funding TigaTx

2020-.. Data Safety Monitoring Board CHOPIN study (LUMC)

2020    Data Safety Monitoring Board ICRA study (NKI)

2020-..  Member Dutch working group Cancer in Pregnancy

2020-.. Congress organization Immune-oncology symposium

2020  Research funding Novartis

2019-.. Scientific chair Dutch Melanoma Treatment Registry (DMTR)

2019-.. Advisory board member patient society Stichting Melanoom

2019-.. Board member Dutch Melanoma Tumor Focus Group

2018-.. Invited discussant Medtalks

Fellowship and Awards

2007  Research year for residents (UU2007-3977) KWF
2008  Translational grant KWF (UU-2008-4217
2008  AGIKO stipend, ZonMW
2008  ASCO Merit Award

2018 ZonMW goed gebruik geneesmiddelen

Research Output (109)

Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study

van der Kooij Monique K, Joosse Arjen, Suijkerbuijk Karijn P M, Aarts Maureen J B, van den Berkmortel Franchette W P J, Blank Christian U, Boers-Sonderen Marye J, van den Eertwegh Alfonsus J M, de Groot Jan Willem B, Haanen John B A G, Hospers Geke A P, Piersma Djura, van Rijn Rozemarijn S, van der Veldt Astrid A M, Vreugdenhil Gerard, Westgeest Hans M, Wouters Michel W J M, Dekkers Olaf M, Kapiteijn Ellen 23 Dec 2022, In: British Journal of Cancer. 128 , p. 707-710 4 p.

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Rohaan Maartje W et al. 8 Dec 2022, In: The New England journal of medicine. 387 , p. 2113-2125 13 p.

Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma:A Nation-Wide Study of the Dutch Melanoma Treatment Registry

Rauwerdink Daan Jan Willem, van Doorn Remco, van der Hage Jos, Van den Eertwegh Alfonsus J M, Haanen John B A G, Aarts Maureen, Berkmortel Franchette, Blank Christian U, Boers-Sonderen Marye J, De Groot Jan Willem B, Hospers Geke A P, de Meza Melissa, Piersma Djura, Van Rijn Rozemarijn S, Stevense Marion, Van der Veldt Astrid, Vreugdenhil Gerard, Wouters Michel W J M, Suijkerbuijk Karijn, van der Kooij Monique, Kapiteijn Ellen 19 Nov 2022, In: Cancers. 14

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma

van Not Olivier J, Verheijden Rik J, van den Eertwegh Alfonsus J M, Haanen John B A G, Aarts Maureen J B, van den Berkmortel Franchette W P J, Blank Christian U, Boers-Sonderen Marye J, de Groot Jan-Willem B, Hospers Geke A P, Kamphuis Anna M, Kapiteijn Ellen, May Anne M, de Meza Melissa M, Piersma Djura, van Rijn Rozemarijn, Stevense-den Boer Marion A, van der Veldt Astrid A M, Vreugdenhil Gerard, Blokx Willeke A M, Wouters Michel J M, Suijkerbuijk Karijn P M 27 Oct 2022, In: JAMA Oncology. 8 , p. 1794-1801 8 p.

Long-term Local Control and Overall Survival After Radiotherapy in Oligoprogressive Patients During Treatment With Checkpoint Inhibitors

Damen Pim J J, Suijkerbuijk Karijn P M, VAN Lindert Anne S R, Eppinga Wietse S C, El Sharouni Sherif Y, Verhoeff Joost J C Oct 2022, In: Anticancer Research. 42 , p. 4795-4804 10 p.

Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review

Ter Maat Laurens S, van Duin Isabella A J, Elias Sjoerd G, van Diest Paul J, Pluim Josien P W, Verhoeff Joost J C, de Jong Pim A, Leiner Tim, Veta Mitko, Suijkerbuijk Karijn P M 9 Sep 2022, In: European Journal of Cancer. 175 , p. 60-76 17 p.

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma

van Not Olivier J, Blokx Willeke A M, van den Eertwegh Alfons J M, de Meza Melissa M, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, de Groot Jan Willem B, Hospers Geke A P, Kapiteijn Ellen, Piersma Djura, van Rijn Rozemarijn S, Stevense-den Boer Marion, van der Veldt Astrid A M, Boers-Sonderen Marye J, Jansen Anne M L, Wouters Michel W J M, Suijkerbuijk Karijn P M Sep 2022, In: JCO Precision Oncology. 6

Metachronous malignancies after response to checkpoint inhibition

de Visser Mirjam A., Verschaeve Francois B., Devriese Lot A., Neyns Bart, Suijkerbuijk Karijn P.M. 17 Aug 2022, In: European Journal of Cancer. 174 , p. 99-101 3 p.

End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma:A Nationwide Cohort Study

van Breeschoten Jesper, Ismail Rawa K, Wouters Michel W J M, Hilarius Doranne L, de Wreede Liesbeth C, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, de Groot Jan Willem B, Hospers Geke A P, Kapiteijn Ellen, Piersma Djura, van Rijn Rozemarijn S, Stevense-den Boer Marion A, van der Veldt Astrid A M, Vreugdenhil Gerard, Boers-Sonderen Marye J, Suijkerbuijk Karijn P M, UMC Amsterdam 9 Aug 2022, In: JCO oncology practice. 18 , p. e1611-e1620

Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands

Heimovaara Joosje H., Boere I. A., de Haan Jorine, van Calsteren Kristel, Amant F., van Zuylen Lia, Lok Christine A.R., Lok C. A.R., van Zuylen L., Boere I. A., Amant F., Beerendonk C. C.M., Bellido-Casado M., Beltman J. J., Bos M. E.M.M., Duvekot J. J., Gerestein C. G., Gordijn S., de Groot C. J.M., van Grotel M., Han S. N., Heeres B. C., van den Heuvel-Eibrink M. M., Houwink A., Huitema D. R., Koken Ph W., Koppert L. B., Lugtenburg P. J., Ottevanger P. B., Painter R. C., Poortmans P. M.P., Roes E. M., van der Scheer L., Schröder C. P., Suelmann B. B.M., Suijkerbuijk K. P.M., van Tienhoven G., van Trommel N. E., Trum J. W., van der Velden J., Vriens I. J.H., Witteveen P. O., Aug 2022, In: European Journal of Cancer. 171 , p. 13-21 9 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet